170 related articles for article (PubMed ID: 35217581)
1. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.
Zeng L; Walsh M; Guyatt GH; Siemieniuk RAC; Collister D; Booth M; Brown P; Farrar L; Farrar M; Firth T; Fussner LA; Kilian K; Little MA; Mavrakanas TA; Mustafa RA; Piram M; Stamp LK; Xiao Y; Lytvyn L; Agoritsas T; Vandvik PO; Mahr A
BMJ; 2022 Feb; 376():e064597. PubMed ID: 35217581
[TBL] [Abstract][Full Text] [Related]
2. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
3. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
4. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.
Walsh M; Collister D; Zeng L; Merkel PA; Pusey CD; Guyatt G; Au Peh C; Szpirt W; Ito-Hara T; Jayne DRW;
BMJ; 2022 Feb; 376():e064604. PubMed ID: 35217545
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.
Xiao Y; Guyatt G; Zeng L; Rw Jayne D; A Merkel P; Ac Siemieniuk R; Dookie JE; A Buchan T; Ahmed MM; J Couban R; Mahr A; Walsh M
BMJ Open; 2022 Feb; 12(2):e050507. PubMed ID: 35217533
[TBL] [Abstract][Full Text] [Related]
6. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Harigai M; Nagasaka K; Amano K; Bando M; Dobashi H; Kawakami T; Kishibe K; Murakawa Y; Usui J; Wada T; Tanaka E; Nango E; Nakayama T; Tsutsumino M; Yamagata K; Homma S; Arimua Y
Mod Rheumatol; 2019 Jan; 29(1):20-30. PubMed ID: 30001655
[TBL] [Abstract][Full Text] [Related]
7. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.
Walsh M; Merkel PA; Peh CA; Szpirt W; Guillevin L; Pusey CD; De Zoysa J; Ives N; Clark WF; Quillen K; Winters JL; Wheatley K; Jayne D;
Trials; 2013 Mar; 14():73. PubMed ID: 23497590
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline.
Ye Z; Reintam Blaser A; Lytvyn L; Wang Y; Guyatt GH; Mikita JS; Roberts J; Agoritsas T; Bertschy S; Boroli F; Camsooksai J; Du B; Heen AF; Lu J; Mella JM; Vandvik PO; Wise R; Zheng Y; Liu L; Siemieniuk RAC
BMJ; 2020 Jan; 368():l6722. PubMed ID: 31907223
[TBL] [Abstract][Full Text] [Related]
9. Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.
Chu X; Hong Y; Wang Y; Yu C; Wang L; Tong H; Yan J; Zhang Z; Xu G; Yao Y; Zeng R
Am J Nephrol; 2021; 52(12):899-908. PubMed ID: 34875652
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
11. PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations.
Casal Moura M; Crowson CS; Specks U; Warrington KJ; Zand L; Sethi S; Fervenza FC
Clin Kidney J; 2023 Mar; 16(3):432-436. PubMed ID: 36865008
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.
Frausová D; Hrušková Z; Lánská V; Lachmanová J; Tesař V
Arthritis Res Ther; 2016 Jul; 18():168. PubMed ID: 27412443
[TBL] [Abstract][Full Text] [Related]
13. Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis.
Gulati K; Pusey CD
Expert Rev Clin Immunol; 2023 Apr; 19(4):417-430. PubMed ID: 36860127
[TBL] [Abstract][Full Text] [Related]
14. Role of therapeutic plasmapheresis in ANCA-associated vasculitis.
Walters G
Pediatr Nephrol; 2016 Feb; 31(2):217-25. PubMed ID: 25986911
[TBL] [Abstract][Full Text] [Related]
15. Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.
Dhaun N; Saunders A; Bellamy CO; Gallardo RM; Manson L; Kluth DC
BMC Musculoskelet Disord; 2015 Nov; 16():343. PubMed ID: 26552432
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Gulati K; Edwards H; Prendecki M; Cairns TD; Condon M; Galliford J; Griffith M; Levy JB; Tam FWK; Tanna A; Pusey CD; McAdoo SP
Kidney Int; 2021 Dec; 100(6):1316-1324. PubMed ID: 34560140
[TBL] [Abstract][Full Text] [Related]
17. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
JAMA; 2021 Jun; 325(21):2178-2187. PubMed ID: 34061144
[TBL] [Abstract][Full Text] [Related]
18. Impact of concurrent glomerulonephritis on outcomes of diffuse alveolar haemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis.
Cohen SP; Wodarcyk AJ; Wong A; Patterson KC; Lyons MI; Barnes A; Strickland A; Pan X; Almaani S; Meara AS; Crouser ED; Wewers MD; Fussner LA
Clin Exp Rheumatol; 2024 Apr; 42(4):811-815. PubMed ID: 37976113
[TBL] [Abstract][Full Text] [Related]
19. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis.
Gregersen JW; Kristensen T; Krag SR; Birn H; Ivarsen P
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S39-47. PubMed ID: 22510451
[TBL] [Abstract][Full Text] [Related]
20. Plasma exchange for the management of ANCA-associated vasculitis: the con position.
Specks U; Fussner LA; Cartin-Ceba R; Casal Moura M; Zand L; Fervenza FC
Nephrol Dial Transplant; 2021 Jan; 36(2):231-236. PubMed ID: 33374017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
